Trial Profile
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Relamorelin (Primary)
- Indications Diabetic gastroparesis
- Focus Therapeutic Use
- Sponsors Rhythm Pharmaceuticals
- 17 Apr 2020 Results assessing the safety and tolerability of relamorelin across phase 2 trials (NCT01571297, NCT02357420) published in the Alimentary Pharmacology and Therapeutics
- 24 Oct 2018 Results presented at the 26th United European Gastroenterology Week
- 08 Oct 2018 According to an Allergan media release, analysis of phase IIa and IIb trial data will be presented at the American College of Gastroenterology Annual Scientific Meeting (ACG) 2018.